Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$1.42	$0.84	$0.55 ▼ $4.42	$101.60M	-0.07	1.09 million shs	108,666 shs
ENLV Enlivex Therapeutics	$0.95 +1.1%	$0.96	$0.81 ▼ $1.76	$22.53M	0.74	127,434 shs	10,503 shs
JMAC Maxpro Capital Acquisition	$6.50	$6.05	$7.50 ▼ $19.22	$87.28M	0.01	74,040 shs	1,503 shs
ZURA Zura Bio	$1.27 +0.4%	$1.21	$0.97 ▼ $5.07	$86.49M	-0.12	431,852 shs	35,958 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	+10.94%	+51.34%	+59.00%	+91.89%	+141,999,900.00%
ENLV Enlivex Therapeutics	-1.88%	+1.29%	-6.08%	-13.58%	-33.66%
JMAC Maxpro Capital Acquisition	0.00%	-0.76%	+14.44%	+1.72%	+2,712.64%
ZURA Zura Bio	-1.56%	+6.78%	+1.61%	+16.67%	-67.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	3.4662 of 5 stars	3.7	5.0	0.0	0.0	2.5	0.8	1.3
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	2.7504 of 5 stars	3.6	1.0	0.0	0.0	3.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTOR Citius Oncology	2.00	Hold	$3.00	111.27% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	949.98% Upside
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A
ZURA Zura Bio	3.13	Buy	$14.33	1,033.07% Upside

Current Analyst Ratings Breakdown

Latest ENLV, CTOR, JMAC, and ZURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00
4/21/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
3/24/2025	ENLV Enlivex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTOR Citius Oncology	N/A	N/A	N/A	N/A	($0.22) per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTOR Citius Oncology	-$21.15M	N/A	0.00	∞	N/A	N/A	-43.67%	-9.74%	N/A
ENLV Enlivex Therapeutics	-$29.07M	-$0.66	N/A	N/A	N/A	N/A	-67.57%	-58.45%	6/13/2025 (Estimated)
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	-$69.24M	-$0.70	N/A	N/A	N/A	N/A	-37.36%	-29.81%	8/12/2025 (Estimated)

Latest ENLV, CTOR, JMAC, and ZURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/13/2025	Q4 2024	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/14/2025	Q2 2025	CTOR Citius Oncology	-$0.09	-$0.11	-$0.02	-$0.11	$5.74 million	N/A
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
3/31/2025	Q4 2024	ENLV Enlivex Therapeutics	-$0.16	-$0.23	-$0.07	-$0.23	N/A	N/A
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTOR Citius Oncology	0.08	0.34	0.08
ENLV Enlivex Therapeutics	N/A	9.71	9.71
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A
ZURA Zura Bio	N/A	10.36	10.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTOR Citius Oncology	70.52%
ENLV Enlivex Therapeutics	1.02%
JMAC Maxpro Capital Acquisition	73.18%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
CTOR Citius Oncology	4.57%
ENLV Enlivex Therapeutics	12.28%
JMAC Maxpro Capital Acquisition	19.27%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTOR Citius Oncology	N/A	71.55 million	55.17 million	N/A
ENLV Enlivex Therapeutics	70	23.65 million	18.78 million	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable
ZURA Zura Bio	3	68.38 million	50.86 million	Optionable

ENLV, CTOR, JMAC, and ZURA Headlines

Recent News About These Companies

Cantor Fitzgerald Weighs in on Zura Bio FY2026 Earnings

June 11 at 8:45 AM | marketbeat.com

Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA)

June 3, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by Brokerages

May 26, 2025 | marketbeat.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

HC Wainwright Issues Positive Estimate for Zura Bio Earnings

May 23, 2025 | marketbeat.com

Q1 Earnings Estimate for Zura Bio Issued By HC Wainwright

May 22, 2025 | marketbeat.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

Zura Bio initiates Phase II systemic sclerosis treatment trial

December 25, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
By Chris Markoch | May 29, 2025
View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
3 Top-Rated Energy Companies Staging Strong Recoveries
By Nathan Reiff | June 2, 2025
View 3 Top-Rated Energy Companies Staging Strong Recoveries
3 Companies to Buy on This Early Cycle Recovery
By Gabriel Osorio-Mazilli | June 3, 2025
View 3 Companies to Buy on This Early Cycle Recovery
Turbulence for Joby Shares: What's Behind the Recent Dip?
By Jeffrey Neal Johnson | May 22, 2025
View Turbulence for Joby Shares: What's Behind the Recent Dip?

ENLV, CTOR, JMAC, and ZURA Company Descriptions

Citius Oncology NASDAQ:CTOR

$1.42 0.00 (0.00%)

As of 10:21 AM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Enlivex Therapeutics NASDAQ:ENLV

$0.95 +0.01 (+1.10%)

As of 10:14 AM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Maxpro Capital Acquisition NASDAQ:JMAC

$6.50 0.00 (0.00%)

As of 06/6/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Zura Bio NASDAQ:ZURA

$1.26 +0.01 (+0.40%)

As of 10:19 AM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time